Serina Therapeutics grants stock options to director
Serina Therapeutics, Inc. reported that director Karen J. Wilson received a grant of stock options covering 15,250 shares of common stock at an exercise price of $1.98 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Serina Therapeutics, Inc. reported that director Karen J. Wilson received a grant of stock options covering 15,250 shares of common stock at an exercise price of $1.98 per share. These options expire on June 17, 2036 and relate to 15,250 underlying common shares.
According to the footnotes, the options will vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, subject to her continued service. A separate row shows she beneficially owns 30,100 common shares, which is an updated holding and not a new transaction.
Insider Trade Summary
Grant/Award: 15,250 shares
Grant/Award
2 txns
Insider
WILSON KAREN J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 15,250 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 15,250 contracts (Direct);
Common Stock — 30,100 shares (Direct)
Footnotes (2)
- F1. This row is being reported to update the previously reported number of shares beneficially owned by the Reporting Person and does not reflect an unreported transaction.
- F2. The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Key Figures
Stock options granted: 15,250 options
Option exercise price: $1.98 per share
Option expiration date: June 17, 2036
+2 more
5 metrics
Stock options granted
15,250 options
Grant to director Karen J. Wilson on June 17, 2026
Option exercise price
$1.98 per share
Exercise price for granted stock options
Option expiration date
June 17, 2036
Expiration for 15,250 stock options
Underlying common shares
15,250 shares
Common stock underlying the granted options
Common shares owned
30,100 shares
Beneficially owned common stock after update
Key Terms
Stock Option (right to buy), beneficially owned, grant date, Annual Meeting
4 terms
Stock Option (right to buy) financial
"Stock Option (right to buy)"
beneficially owned financial
"update the previously reported number of shares beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
grant date financial
"the one-year anniversary of the grant date"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
Annual Meeting financial
"the day before the next Annual Meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Serina Therapeutics (SER) report for Karen J. Wilson?
Serina Therapeutics reported that director Karen J. Wilson received a grant of stock options for 15,250 shares of common stock at an exercise price of $1.98 per share. The filing also updated her reported beneficial ownership of 30,100 common shares.
What are the key terms of Karen J. Wilson’s new stock options at Serina Therapeutics (SER)?
The new stock options cover 15,250 shares of Serina Therapeutics common stock with an exercise price of $1.98 per share. They expire on June 17, 2036 and vest based on service through either the next Annual Meeting or one year from grant.
How and when will Karen J. Wilson’s Serina Therapeutics (SER) stock options vest?
The options will vest on the earlier of the day before Serina Therapeutics’ next Annual Meeting or the one-year anniversary of the grant date. Vesting is conditioned on Karen J. Wilson’s continued service to the company through the applicable vesting date.
What is Karen J. Wilson’s reported common stock ownership in Serina Therapeutics (SER)?
The filing shows Karen J. Wilson beneficially owns 30,100 shares of Serina Therapeutics common stock after the reported update. A footnote explains this row simply updates previously reported ownership and does not represent a new purchase, sale, or other transaction.
Does the Serina Therapeutics (SER) Form 4 indicate any stock sales by Karen J. Wilson?
The Form 4 does not report any stock sales by Karen J. Wilson. It shows a grant of stock options and an ownership row that updates her previously reported 30,100-share holding, specifically stating the holding entry does not reflect an unreported transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates